Study design
This study was conducted according to Good Clinical Practice Guidelines, the Declaration of Helsinki (2000), and the United States 21 Code of Federal Regulations (ClinicalTrials.gov identifier: NCT01925716). The study protocol and informed consent documents were approved by an institutional review board (Quorum Review IRB, Seattle, WA). A signed informed consent form and authorization for disclosure of protected health information were obtained from all subjects before protocol-specific procedures were carried out. Staff and subjects remained blinded to treatment throughout the trial.